ATE508113T1 - Indolinverbindung und verfahren zu deren herstellung - Google Patents

Indolinverbindung und verfahren zu deren herstellung

Info

Publication number
ATE508113T1
ATE508113T1 AT05795703T AT05795703T ATE508113T1 AT E508113 T1 ATE508113 T1 AT E508113T1 AT 05795703 T AT05795703 T AT 05795703T AT 05795703 T AT05795703 T AT 05795703T AT E508113 T1 ATE508113 T1 AT E508113T1
Authority
AT
Austria
Prior art keywords
production
propyl
phenoxy
dihydro
ethyl
Prior art date
Application number
AT05795703T
Other languages
English (en)
Inventor
Toshiaki Yamaguchi
Ikuo Tsuchiya
Ken Kikuchi
Takashi Yanagi
Original Assignee
Kissei Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical filed Critical Kissei Pharmaceutical
Application granted granted Critical
Publication of ATE508113T1 publication Critical patent/ATE508113T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT05795703T 2004-10-27 2005-10-24 Indolinverbindung und verfahren zu deren herstellung ATE508113T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004313040 2004-10-27
PCT/JP2005/019478 WO2006046499A1 (ja) 2004-10-27 2005-10-24 インドリン化合物およびその製造方法

Publications (1)

Publication Number Publication Date
ATE508113T1 true ATE508113T1 (de) 2011-05-15

Family

ID=36227738

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05795703T ATE508113T1 (de) 2004-10-27 2005-10-24 Indolinverbindung und verfahren zu deren herstellung

Country Status (18)

Country Link
US (1) US7834193B2 (de)
EP (1) EP1806340B1 (de)
JP (1) JP5049013B2 (de)
KR (1) KR101249865B1 (de)
CN (1) CN101048376B (de)
AT (1) ATE508113T1 (de)
AU (1) AU2005298078B2 (de)
BR (1) BRPI0517515B8 (de)
CA (1) CA2583660C (de)
DE (1) DE602005027881D1 (de)
ES (1) ES2362788T3 (de)
HK (1) HK1113364A1 (de)
IL (1) IL182642A (de)
MX (1) MX2007005126A (de)
RU (1) RU2379289C2 (de)
TW (1) TW200621709A (de)
WO (1) WO2006046499A1 (de)
ZA (1) ZA200703996B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA78854C2 (en) * 2002-09-06 2007-04-25 Kissei Pharmaceutical Crystal for an oral solid drug and oral solid drug for dysuria treatment containing the same
WO2008106125A2 (en) 2007-02-26 2008-09-04 Concert Pharmaceuticals, Inc. Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists
US20080242717A1 (en) * 2007-02-28 2008-10-02 Fumiyasu Sato Methods for treating benign prostatic hyperplasia
CN101585798B (zh) * 2008-05-20 2011-06-15 浙江华海药业股份有限公司 光学活性化合物1-(3-苯甲酰氧基丙基)-5-(2-(1-苯基乙基胺)丙基)-7-氰基吲哚啉及其制备方法和用途
CN101993405B (zh) * 2009-08-27 2014-01-15 浙江华海药业股份有限公司 吲哚啉衍生物、及其制备方法和用途
CN101993406B (zh) * 2009-08-27 2014-01-15 浙江华海药业股份有限公司 光学活性的吲哚啉化合物及其制备方法
CN101993407B (zh) * 2009-08-27 2014-01-29 浙江华海药业股份有限公司 用于制备西洛多辛的吲哚啉化合物及其制备方法
US8471039B2 (en) 2009-09-12 2013-06-25 Sandoz Ag Process for the preparation of indoline derivatives and their intermediates thereof
CN101768056B (zh) * 2010-01-19 2013-10-16 扬子江药业集团有限公司 一种取代的苯基甲基醚的制备方法
WO2011101864A1 (en) 2010-02-17 2011-08-25 Panacea Biotec Ltd Novel process for the synthesis of phenoxyethyl derivatives
WO2011124704A1 (en) 2010-04-09 2011-10-13 Ratiopharm Gmbh Process for preparing an intermediate for silodosin
CN102311319A (zh) * 2010-07-05 2012-01-11 浙江华海药业股份有限公司 一种制备2-(2,2,2-三氟乙基)苯甲醚的方法
WO2012014186A1 (en) * 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Process for the preparation of silodosin and its novel intermediates
CN102229557B (zh) * 2010-08-05 2013-03-27 南京海纳医药科技有限公司 西洛多辛的半水合物晶体、制备方法和包含它的药物组合物
CN102229558B (zh) * 2010-08-05 2013-05-08 南京海纳医药科技有限公司 西洛多辛的晶型δ、它的制备方法和包含它的药物组合物
WO2012062229A1 (en) 2010-11-12 2012-05-18 Zentiva, K.S. A method of manufacturing (-)-l-(3-hydroxypropyl)-5-[(2r)-2-({2,2,2-trifluoroethoxy)- phenoxyethyl}amino)propyl]-2,3-dihydro-lh-indole-7-carboxamide
CZ2010836A3 (cs) * 2010-11-12 2012-03-14 Zentiva, K.S. Zpusob výroby (-)-1-(3-hydroxypropyl)-5-[(2R)-2-({2,2,2-trifluorethoxy)fenoxyethyl}amino)propyl]-2,3-dihydro-1H-indol-7-karboxamidu
CZ2010837A3 (cs) * 2010-11-12 2012-03-14 Zentiva, K.S. Zpusob výroby (-)-1-(3-hydroxypropyl)-5-[(2R)-2-({2,2,2-trifluorethoxy)fenoxyethyl}amino)propyl]-2,3-dihydro-1H-indol-7-karboxamidu
WO2012131710A2 (en) 2011-03-30 2012-10-04 Panacea Biotec Ltd Novel process for the synthesis of indoline derivatives
WO2012147019A1 (en) * 2011-04-26 2012-11-01 Orchid Chemicals And Pharamceuticals Limited An improved process for the preparation of silodosin
WO2012147107A2 (en) * 2011-04-29 2012-11-01 Msn Laboratories Limited Novel & improved processes for the preparation of indoline derivatives and its pharmaceutical composition
CN102382029B (zh) * 2011-07-26 2016-06-29 浙江华海药业股份有限公司 一种西洛多辛中间体成盐制备方法
WO2013072935A2 (en) 2011-10-10 2013-05-23 Cadila Healthcare Limited Process for the preparation of silodosin
ES2639196T3 (es) 2011-10-21 2017-10-25 Sandoz Ag Método para preparar silodosina
CN102675182B (zh) * 2012-05-24 2014-03-26 临海天宇药业有限公司 1-(3-苯甲酰氧基丙基)-5-(2-羰基丙基)-7-腈基吲哚啉的制备方法
WO2014118606A2 (en) * 2013-01-29 2014-08-07 Alembic Pharmaceuticals Limited A novel process for the preparation of silodosin
CN103159664B (zh) * 2013-03-29 2016-03-23 深圳市海滨制药有限公司 一种赛洛多辛原料药及其制备方法、药物组合物
CN104140389A (zh) * 2013-05-06 2014-11-12 昆明积大制药股份有限公司 一种赛洛多辛及其中间体的制备方法
CN103420893B (zh) * 2013-08-02 2015-11-25 江苏和成新材料有限公司 制备西洛多辛中间体的方法
WO2015119057A1 (ja) 2014-02-06 2015-08-13 宇部興産株式会社 インドリン化合物の製造方法
KR20150098565A (ko) * 2014-02-20 2015-08-28 한미정밀화학주식회사 실로도신 제조에 사용되는 신규 중간체, 이의 제조방법 및 이를 이용한 실로도신의 제조방법
KR20150127996A (ko) * 2014-05-08 2015-11-18 한미정밀화학주식회사 실로도신 감마형 결정의 제조방법
JP6242298B2 (ja) * 2014-06-13 2017-12-06 株式会社トクヤマ １−（３−ベンゾイルオキシプロピル）−７−シアノ−５−［（２ｒ）−２−（｛２−［２−（２，２，２−トリフルオロエトキシ）フェノキシ］エチル｝アミノ）プロピル］インドリンまたはその塩を製造する方法
KR101628946B1 (ko) * 2014-07-09 2016-06-09 동방에프티엘(주) 실로도신의 개선된 제조방법
KR101725393B1 (ko) * 2014-07-24 2017-04-27 주식회사 경보제약 실로도신의 제조 방법 및 신규 중간체
WO2016042441A1 (en) 2014-09-18 2016-03-24 Mankind Research Centre A novel process for the preparation of considerably pure silodosin
JP2016088847A (ja) * 2014-10-30 2016-05-23 株式会社トクヤマ （‐）‐１‐（３‐ヒドロキシプロピル）‐５‐［［（２ｒ）‐２‐（｛２‐［２‐（２，２，２‐トリフルオロエトキシ）フェノキシ］エチル｝アミノ）プロピル］‐２，３‐ジヒドロ‐１ｈ‐インドール‐７‐カルボキサミド］）の製造方法
CN104478784B (zh) * 2014-11-17 2017-02-22 武汉工程大学 一种西洛多辛草酸盐的晶型及其制备方法
KR101694262B1 (ko) * 2014-12-18 2017-01-10 (주)다산메디켐 실로도신의 결정형의 제조방법
US9356405B1 (en) 2015-03-05 2016-05-31 Sony Corporation Connector tongue element for an electrical connector plug receptacle and a method for producing the same
WO2017051324A1 (en) * 2015-09-23 2017-03-30 Biocon Limited The process of preparing indoline compounds and a novel indoline salt
JP7054381B2 (ja) 2015-09-23 2022-04-13 バイオコン・リミテッド 結晶形態のポサコナゾール中間体および非晶質ポサコナゾールの調製のためのプロセス
ES2607639B1 (es) * 2015-09-30 2018-02-28 Urquima, S.A Sal de ácido maleico de un intermedio de silodosina
CN106995399A (zh) * 2016-01-25 2017-08-01 北京天泰恒华医药技术有限公司 一种制备赛洛多辛的方法
KR102365411B1 (ko) * 2017-08-08 2022-02-21 (주)헥사파마텍 신규의 설폰아마이드 중간체 및 이를 사용한 실로도신의 제조방법
KR102163068B1 (ko) * 2018-07-04 2020-10-07 주식회사 가피바이오 실로도신 합성용 중간체의 제조 방법 및 이를 이용한 실로도신의 제조 방법
CN111217735B (zh) * 2018-11-27 2023-03-14 上海汇伦医药股份有限公司 赛洛多辛中间体的制备方法
WO2020237645A1 (zh) * 2019-05-31 2020-12-03 上海汇伦生命科技有限公司 赛洛多辛中间体的制备方法
CN110452149B (zh) * 2019-06-13 2021-11-02 北京鑫开元医药科技有限公司 二氢吲哚化合物的制备方法、二氢吲哚化合物及用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0600675B1 (de) * 1992-12-02 1998-07-08 Kissei Pharmaceutical Co., Ltd. Indolin Verbindungen zur Behandlung von Dysurien
JP3331047B2 (ja) * 1994-06-01 2002-10-07 キッセイ薬品工業株式会社 インドリン誘導体
JP2526811B2 (ja) * 1994-07-22 1996-08-21 田辺製薬株式会社 フェネチルアミン誘導体及びその製法
BR9908301A (pt) * 1998-02-27 2000-10-31 Kissei Pharmaceutical Derivados de indol e composições farmacêuticas que compreendem os mesmos
JP4634560B2 (ja) * 2000-01-14 2011-02-16 キッセイ薬品工業株式会社 光学活性なインドリン誘導体の製造方法およびその製造中間体
JP4921646B2 (ja) * 2001-03-08 2012-04-25 キッセイ薬品工業株式会社 １−（３−ベンジルオキシプロピル）−５−（２−置換プロピル）インドリン誘導体およびその使用方法
JP2006188470A (ja) * 2005-01-07 2006-07-20 Kissei Pharmaceut Co Ltd インドリン誘導体およびその製造方法

Also Published As

Publication number Publication date
AU2005298078B2 (en) 2011-03-31
US20070197627A1 (en) 2007-08-23
JP5049013B2 (ja) 2012-10-17
HK1113364A1 (en) 2008-10-03
IL182642A (en) 2012-10-31
ES2362788T3 (es) 2011-07-13
BRPI0517515A (pt) 2008-10-14
KR20070084499A (ko) 2007-08-24
AU2005298078A1 (en) 2006-05-04
BRPI0517515B8 (pt) 2021-05-25
JPWO2006046499A1 (ja) 2008-05-22
DE602005027881D1 (de) 2011-06-16
BRPI0517515B1 (pt) 2021-03-09
TW200621709A (en) 2006-07-01
MX2007005126A (es) 2007-07-04
RU2379289C2 (ru) 2010-01-20
EP1806340A1 (de) 2007-07-11
CA2583660C (en) 2013-02-12
KR101249865B1 (ko) 2013-04-02
CN101048376B (zh) 2011-03-23
WO2006046499A1 (ja) 2006-05-04
IL182642A0 (en) 2007-07-24
CN101048376A (zh) 2007-10-03
TWI356819B (de) 2012-01-21
US7834193B2 (en) 2010-11-16
CA2583660A1 (en) 2006-05-04
ZA200703996B (en) 2008-09-25
RU2007115888A (ru) 2008-11-10
EP1806340A4 (de) 2009-08-12
EP1806340B1 (de) 2011-05-04

Similar Documents

Publication Publication Date Title
ATE508113T1 (de) Indolinverbindung und verfahren zu deren herstellung
Han et al. Discovery of ARD-69 as a highly potent proteolysis targeting chimera (PROTAC) degrader of androgen receptor (AR) for the treatment of prostate cancer
CN1280266C (zh) 酰基苯基脲衍生物,其制备方法和作为药物的用途
Hwang et al. Orally bioavailable potent soluble epoxide hydrolase inhibitors
RU2412934C2 (ru) Применение антагонистов crth2 в терапии
ES2469849T3 (es) Derivados deuterados de isoindolin-1,3-diona como inhibidores de PDE4 y TNF-alfa
CN1174956C (zh) 作为IL-1β和TNF-α的抑制剂的氨基二苯酮
RU2005118409A (ru) Новые гидроксииндолы, их применение в качестве ингибиторов фосфодиэстеразы 4 и способ их получения
RU2005108668A (ru) Индолы, обладающие противодиабетической активностью
Porcheddu et al. From lossen transposition to solventless “Medicinal Mechanochemistry”
JP2005527492A5 (de)
AR069530A1 (es) Procedimiento para la fabricacion de un derivado de indolinona
RU2315041C2 (ru) Производные 2,6-хинолинила и 2,6-нафтила, фармацевтические композиции на их основе, их применение в качестве ингибиторов vla-4 и промежуточные соединения
UY29389A1 (es) Derivados sustituidos del ácido1-((4-((((3,3-dimetil-2-oxo-2,3-dihidro-1h-indol-1-il)carbonil)amino)metil)piperidin-1-il)metil)ciclobutanocarboxílico, sales farmaceuticamente aceptables, composiciones que los contienen y aplicaciones.
CA2688815A1 (fr) Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
Scott et al. Mitsunobu inversion of a secondary alcohol with diphenylphosphoryl azide. Application to the enantioselective multikilogram synthesis of a HCV polymerase inhibitor
Boger et al. Synthesis, chemical properties, and biological evaluation of CC-1065 and duocarmycin analogues incorporating the 5-methoxycarbonyl-1, 2, 9, 9a-tetrahydrocyclopropa [c] benz [e] indol-4-one alkylation subunit
EA200500095A1 (ru) Производные 4-(7-гало-2-хино(кса-)линилокси)феноксипропионовой кислоты в качестве противоопухолевых средств
JP2006523626A5 (de)
Bertram et al. Desmethyl SuFEx-IT: SO2F2-Free Synthesis and Evaluation as a Fluorosulfurylating Agent
AR047748A1 (es) Derivados de 3,5 - dioxo - (2h, 4h) - 1,2,4 - triazina activadores de los receptores ppar alfa y/o gamma, su preparacion, su uso en composiciones farmaceuticas y su empleo en el tratamiento de trastornos metabolicos.
AR037679A1 (es) Un procedimiento para preparar una mezcla de rotameros de 4-[4-[(1r)-[4-(trifluormetil) fenil]-2-metoxietil] - (3s) - metil - 1- piperazinil] - 4- metil-1-[4,6-dimetil-5-pirimidinil) carbonilo], una mezcla de rotameros preparado por dicho procedimiento, y sales farmaceuticas de dicho compuesto basic
PE20081142A1 (es) Formulaciones semisolidas de inhibidores de enzima fosfolipasa
RU2375357C2 (ru) Производные пиразолилиндолила в качестве активаторов ppar
CN1048718C (zh) 苯乙胺类和苯丙胺类化合物及其制备方法和其药物制剂及其应用

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties